Trust Signals
Last updated: May 29, 2026.
Evidence policy: Every claim is graded. Speculative statements are labeled. No statistics are invented.
Conflicts: FormBlends sells research-grade diluents. This page presents honest trade-offs including when to use competing products.
Key Takeaways
- Bacteriostatic water contains exactly 0.9% benzyl alcohol by volume, which is the single feature that separates it from plain sterile water for injection.
- Its primary use is reconstituting multi-dose injectable compounds, peptides, and recombinant proteins where repeated vial entry is needed over days to weeks.
- USP-consistent practice supports a 28-day in-use period after first puncture when handled aseptically and stored per label.
- It is contraindicated in neonates due to benzyl alcohol accumulation causing gasping syndrome, an FDA-documented risk.
- A legitimate certificate of analysis must confirm benzyl alcohol at 0.9%, pH 4.5 to 7.0, sterility pass, and endotoxin below 0.25 EU per mL.
What Bacteriostatic Water Is Used For: Direct Answer
Bacteriostatic water is used to reconstitute or dilute injectable medications, peptides, and protein-based compounds that require multiple draws from one vial. The 0.9% benzyl alcohol it contains stops bacterial regrowth after puncture, giving it a practical multi-dose lifespan of up to 28 days that plain sterile water cannot match.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What bacteriostatic water is and what it contains
- How the 0.9% benzyl alcohol actually works
- Evidence ledger: what the science does and does not prove
- What most pages get wrong about bacteriostatic water
- Honest head-to-head: bacteriostatic water vs. sterile water vs. bacteriostatic saline
- Reconstitution math and operational literacy
- Stability, storage, and signs of degradation
- How to read a label and COA
- Safety boundaries, contraindications, and the neonatal warning
- FAQ
- Sources
- Footer disclaimers
What Is Bacteriostatic Water and What Does It Contain?
Bacteriostatic water for injection (BWI) is sterile water with a single added preservative: benzyl alcohol at 0.9% (9 mg per mL). That is the complete ingredient list per USP and FDA-approved labeling. It is not saline, it is not buffered, and it is not the same product as "sterile water for injection," which contains no preservative at all.
The word bacteriostatic is precise: the benzyl alcohol does not kill all bacteria outright (bactericidal), it inhibits their proliferation. This distinction matters because a grossly contaminated vial, one entered with a non-sterile needle or left uncapped, is not rescued by benzyl alcohol.
BWI is sold in multi-dose vials, typically 30 mL, because multi-dose use is its entire reason for existing. Single-dose use of BWI is permitted but wasteful; plain sterile water for injection covers that case at lower cost.
How the 0.9% Benzyl Alcohol Actually Works
Benzyl alcohol is an aromatic alcohol (C7H8O). At 0.9% in an aqueous solution, it acts on bacteria by two main mechanisms established in pharmacological literature:
- Membrane disruption: Benzyl alcohol partitions into bacterial lipid bilayers, increasing membrane fluidity and impairing ion gradients. This is concentration-dependent; at 0.9% it inhibits growth rather than causing rapid cell lysis.
- Enzyme inhibition: It inhibits bacterial dehydrogenases and other membrane-associated enzymes involved in energy metabolism, slowing replication.
What this mechanism does NOT prove: benzyl alcohol at 0.9% does not eliminate fungal contamination reliably, and it offers no protection against endotoxins (pyrogens) already present from gram-negative bacterial cell walls. A vial that passed sterility testing at manufacture but was stored improperly before use could still carry endotoxin load that benzyl alcohol does nothing to reduce.
In human tissue, benzyl alcohol is metabolized by hepatic aldehyde dehydrogenase to benzoic acid and then conjugated to hippuric acid for renal excretion. Adult hepatic capacity handles the small amounts in typical reconstitution volumes without accumulation. Neonatal hepatic capacity does not.
Evidence Ledger: What the Science Does and Does Not Prove
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| 0.9% benzyl alcohol inhibits bacterial growth in aqueous solution | Pharmacopoeial testing (USP Antimicrobial Effectiveness Testing) | Positive, well established | High |
| 28-day in-use period after first puncture is safe with aseptic technique | Regulatory/compendial guidance, not prospective RCT in end-users | Directionally supported | Moderate |
| Benzyl alcohol causes gasping syndrome in neonates | Case series and FDA safety communication (1982) | Harm established | High |
| BWI is compatible with most lyophilized peptides | Manufacturer compatibility data, formulation chemistry; no broad RCT | Generally positive | Moderate |
| BWI at 0.9% BA accelerates aggregation in some proteins | Formulation science literature (mechanistic); context-specific | Risk present at higher BA concentrations, less clear at 0.9% | Low to Moderate |
| BWI reduces infection risk vs. sterile water in multi-draw settings | Indirect; pharmacopoeial rationale; no controlled human trial comparing infection rates | Plausible but not RCT-proven | Low |
| Endotoxin in BWI is controlled to below 0.25 EU per mL | USP regulatory standard for water for injection class products | Regulatory requirement | High (if product meets USP) |
What Most Pages Get Wrong About Bacteriostatic Water
This is the section commodity pages skip entirely.
1. Benzyl alcohol does not protect against your own technique failures. BWI's bacteriostatic action requires that the initial bacterial load in the vial stays low. If you inject air into the vial with a contaminated needle, or if the rubber stopper is cored (a rubber fragment punched into the solution), the benzyl alcohol concentration in a 30 mL vial is diluted and the contamination load introduced can overwhelm it.
2. "Sterile" on the label does not mean endotoxin-free. Bacterial endotoxins (lipopolysaccharides from gram-negative bacteria) survive sterilization. A poorly manufactured batch of BWI can be sterile and still cause fever and systemic inflammatory response after injection. Only endotoxin testing (Limulus Amebocyte Lysate assay or equivalent) catches this. The COA must show endotoxin results, not just sterility.
3. The 28-day window assumes consistent refrigeration in many reconstituted formulations, but is not a hard expiry for the BWI itself. The 28-day rule applies to multi-dose vials of compounded or reconstituted products under USP 797. The BWI vial's own manufacturer expiry can be years out. Confusing these two timelines is common and consequential.
4. Not all peptide vials tolerate repeated temperature cycling. Each time you draw from a reconstituted peptide vial, you introduce a brief warming. Over multiple draws, cumulative thermal stress degrades many peptides faster than the bacteriostatic protection matters. The limiting factor for reconstituted peptide stability is usually the peptide bond chemistry, not bacterial contamination.
5. Research-grade BWI is not the same as pharmaceutical-grade BWI. Vials not manufactured under USP 1, cGMP, or equivalent standards may have correct benzyl alcohol concentration but inadequate endotoxin or particulate testing. Always confirm the grade of the product you are sourcing.
Honest Head-to-Head: BWI vs. Sterile Water vs. Bacteriostatic Saline
| Feature | Bacteriostatic Water (BWI) | Sterile Water for Injection (SWFI) | Bacteriostatic Normal Saline (0.9% NaCl + 0.9% BA) |
|---|---|---|---|
| Preservative | 0.9% benzyl alcohol | None | 0.9% benzyl alcohol |
| Tonicity | Hypotonic | Hypotonic | Isotonic |
| Multi-dose use | Yes, up to 28 days | No, single use only | Yes, up to 28 days |
| Neonatal use | Contraindicated | Acceptable (check indication) | Contraindicated |
| Best for peptides | Yes (most common choice) | Single-dose reconstitution only | When isotonicity matters for the route |
| Where BWI loses | Neonates, benzyl-alcohol-sensitive drugs, single-dose efficiency | Wins on neonatal and single-dose safety | Wins on tonicity; adds sodium load |
| Cost | Low | Lowest | Low |
Honest concession: if you are reconstituting a single-use peptide vial that will be fully drawn in one sitting, SWFI is equally appropriate and avoids any benzyl alcohol exposure. BWI's advantage exists only when you need multiple draws from a single vial over time.
Reconstitution Math and Operational Literacy
The most common reconstitution error is adding too much or too little diluent and then miscalculating the concentration drawn per unit of volume.
Formula: Concentration (mcg per mL) = Total peptide mass (mcg) divided by volume of BWI added (mL).
Worked example: A vial contains 5 mg (5,000 mcg) of lyophilized peptide. You add 2 mL of BWI.
- Concentration = 5,000 mcg divided by 2 mL = 2,500 mcg per mL.
- On a 100-unit insulin syringe (where 100 units = 1 mL), each 10-unit mark = 0.1 mL = 250 mcg.
- If your dose is 500 mcg, you draw to the 20-unit mark.
Key technique points:
- Add BWI slowly down the side of the vial, not directly onto the lyophilized cake. Forceful injection can shear peptide structure.
- Swirl gently; never shake. Vigorous agitation promotes aggregation and foaming, both of which degrade peptide integrity.
- Allow the solution to reach room temperature before drawing if stored refrigerated, to avoid thermal shock to the plunger seal of the syringe.
Stability, Storage, and Signs of Degradation
BWI vial unopened: Store at controlled room temperature (typically 20 to 25 degrees Celsius per USP). Avoid freezing; benzyl alcohol can precipitate and may not fully re-dissolve uniformly. Protect from light.
After reconstituting a peptide: Refrigerate at 2 to 8 degrees Celsius. Do not freeze reconstituted peptide solutions unless the specific peptide's stability data supports it.
Signs of BWI degradation:
- Visible cloudiness or particulates: discard immediately.
- Off or rancid odor: benzyl alcohol oxidizes over time to benzaldehyde and then benzoic acid, producing a smell that is sharper or more acrid than the normal faint solvent scent. Discard.
- Discoloration (yellowing): discard.
- Rubber particulates from stopper coring: discard.
Chemistry behind the rule: Benzyl alcohol (C6H5CH2OH) undergoes oxidation to benzaldehyde (C6H5CHO) and further to benzoic acid (C6H5COOH). This pathway is accelerated by heat, UV light, and repeated temperature cycling. When benzyl alcohol concentration has fallen significantly due to oxidation or evaporation through a repeatedly punctured stopper, the bacteriostatic action weakens before you would visually detect any problem. This is why the 28-day rule exists as a time limit even in visually clear vials.
How to Read a Label and Certificate of Analysis
A pharmaceutical-grade BWI label must state:
- "Bacteriostatic Water for Injection, USP" or equivalent pharmacopoeial designation.
- Benzyl alcohol 0.9% as the preservative, explicitly named.
- Route: "For intramuscular, intravenous, or subcutaneous use."
- The neonatal warning (required by FDA).
- Lot number and expiry date.
A legitimate COA should include:
| Test | What to Look For | Red Flag |
|---|---|---|
| Benzyl alcohol assay | 0.9% within stated tolerance (often plus or minus 10%) | Missing, or result far outside tolerance |
| pH | 4.5 to 7.0 | Outside this range suggests formulation error |
| Sterility | "Passes USP sterility test" or equivalent | No sterility data at all |
| Endotoxins (LAL) | Below 0.25 EU per mL (USP water for injection standard) | Not tested, or result above limit |
| Particulate matter | Passes USP 788 or equivalent | Not listed |
| Manufacturer | FDA-registered facility (check FDA's drug establishment database) | No facility information |
Safety Boundaries, Contraindications, and the Neonatal Warning
The FDA issued a Drug Safety Communication in 1982 documenting neonatal deaths associated with benzyl alcohol used as a flush in intensive care nurseries. The mechanism is accumulation: neonates lack the hepatic aldehyde dehydrogenase activity to clear benzaldehyde efficiently, leading to metabolic acidosis and the "gasping syndrome." This is an established, high-confidence risk. Bacteriostatic water is absolutely contraindicated in neonates.
For adults, the benzyl alcohol dose from typical reconstitution volumes (0.1 to 0.5 mL of diluent per injection) is a small fraction of the doses associated with toxicity in adults. No accumulation risk has been documented in healthy adults at these doses.
Additional considerations:
- Patients with documented benzyl alcohol hypersensitivity should use SWFI instead.
- Intravenous use of large volumes of BWI (as a vehicle in IV infusions rather than as a small reconstitution volume) carries greater benzyl alcohol exposure; this is a different clinical context from subcutaneous peptide reconstitution.
- Hypotonic solutions injected in large volumes IM or SC can cause local pain; this is a property of BWI and SWFI alike, and is usually not clinically significant at peptide reconstitution volumes.
FAQ
What is bacteriostatic water used for?
Bacteriostatic water is used to reconstitute or dilute injectable medications, peptides, and protein-based compounds such as human growth hormone. The 0.9% benzyl alcohol it contains prevents bacterial regrowth, making the vial safe to re-enter multiple times over a multi-week period, typically up to 28 days after first puncture.
Why does bacteriostatic water contain benzyl alcohol?
Benzyl alcohol at 0.9% disrupts bacterial cell membranes and inhibits metabolic enzymes, preventing regrowth after the vial is punctured. It does not sterilize the water outright but stops bacteria from multiplying, which is why the term is bacteriostatic rather than bactericidal.
How long can a vial of bacteriostatic water be used after opening?
USP guidance and manufacturer labeling typically support use for up to 28 days after first puncture when stored at room temperature and handled with aseptic technique. Beyond that point, benzyl alcohol concentration may have declined through oxidation and cumulative contamination risk increases.
Can bacteriostatic water be used with all peptides?
Most lyophilized peptides reconstitute well in bacteriostatic water. However, peptides sensitive to benzyl alcohol or those intended for single-dose use may perform better with sterile water for injection instead. Always check the specific peptide's reconstitution notes or COA for diluent compatibility information.
What is the difference between bacteriostatic water and sterile water for injection?
Sterile water for injection contains no preservative and must be used in a single session; any remainder is discarded. Bacteriostatic water contains 0.9% benzyl alcohol, allowing multiple draws from one vial. Sterile water is required for neonates and for drugs incompatible with benzyl alcohol.
Is bacteriostatic water the same as saline?
No. Bacteriostatic water contains only water and 0.9% benzyl alcohol. Normal saline contains 0.9% sodium chloride and no benzyl alcohol. Bacteriostatic saline combines both. Using the wrong diluent can alter tonicity and drug compatibility, so matching the labeled diluent to the compound matters.
How do I calculate how much bacteriostatic water to add when reconstituting a peptide?
Divide the total peptide mass by your desired concentration per unit volume. For example, 5 mg of peptide dissolved in 2 mL of bacteriostatic water gives 2,500 mcg per mL. On a 100-unit insulin syringe, each 10-unit mark equals 0.1 mL, so 250 mcg per mark at that concentration.
Can bacteriostatic water be used intramuscularly and subcutaneously?
Yes, bacteriostatic water is approved for use as a diluent for both intramuscular and subcutaneous injections. The benzyl alcohol at 0.9% is well below thresholds associated with local tissue toxicity when used at typical small reconstitution volumes.
Why is bacteriostatic water contraindicated in newborns?
Neonates lack efficient hepatic enzyme capacity to metabolize benzyl alcohol. Accumulation causes gasping syndrome, a serious and potentially fatal condition documented in an FDA safety communication from 1982. Sterile water for injection or preservative-free saline must be used in neonates instead.
How do I know if my bacteriostatic water has degraded?
Visible particulates, cloudiness, or color change mean discard immediately. A faint benzyl alcohol odor is normal. If you detect a sharp or rancid smell, benzyl alcohol has oxidized to benzaldehyde or benzoic acid and the vial should be discarded. Rubber fragments from stopper coring also require immediate discard.
What should a certificate of analysis for bacteriostatic water show?
A legitimate COA should confirm benzyl alcohol content at 0.9% within tolerance, pH between 4.5 and 7.0, sterility testing pass, and endotoxin levels below 0.25 EU per mL. Missing endotoxin data is a significant red flag regardless of sterility results.
Does bacteriostatic water affect peptide stability after reconstitution?
Benzyl alcohol is generally compatible with most peptides at 0.9% concentration. However, it is a mild organic solvent that in some formulation contexts can influence protein aggregation behavior. Refrigeration at 2 to 8 degrees Celsius after reconstitution is the most important stability measure regardless of which diluent is used.
Sources
- United States Pharmacopeia. Bacteriostatic Water for Injection monograph. USP-NF. Current edition.
- United States Pharmacopeia. General Chapter 51: Antimicrobial Effectiveness Testing. USP-NF.
- United States Pharmacopeia. General Chapter 788: Particulate Matter in Injections. USP-NF.
- United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding, Sterile Preparations. USP-NF.
- FDA Drug Safety Communication: Serious and Fatal Pediatric Cases of Gasping Syndrome Associated with Benzyl Alcohol. FDA, 1982 (and subsequent label requirements).
- Gershanik J, Boecler B, Ensley H, McCloskey S, George W. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982;307(22):1384-1388.
- Nair B. Final report on the safety assessment of benzyl alcohol, benzoic acid, and sodium benzoate. Int J Toxicol. 2001;20 Suppl 3:23-50.
- Akers MJ. Parenteral Quality Control: Sterility, Pyrogen, Particulate, and Package Integrity Testing. 3rd ed. Marcel Dekker; 2002.
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-188.
- FDA. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. Current Good Manufacturing Practice. September 2004.